Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...
Tokyo's benchmark Nikkei 225 index has dipped more than 4% and most other markets in Asia also sank after a retreat on Wall ...
Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...
The bidding war over biotechnology company Metsera (MTSR) has intensified, drawing fierce competition from pharmaceutical ...
NEW YORK (AP) — Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the ...
The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.
Pfizer CEO Albert Bourla called Novo Nordisk's bid for obesity drug developer Metsera an "illegal...end-run around antitrust laws." ...
Revenue was down 5.9% from last year to $16.654, after increasing 10% the previous quarter. These results were better than ...
Denmark's Novo Nordisk said Tuesday it would replace more than half of its board, including the chair, as the Ozempic and Wegovy maker restructures in the face of rising competition for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback